Systemic Hormone Therapy During Menopause May Up Risk for Depression
Initiating systemic hormone therapy before age 50 years linked to increased risk for depression
Menopause and HRT
MPR Weekly Dose Podcast #137
USPSTF recommendations on estrogen and progesterone; semaglutide assessed in obese teenagers; efficacy and safety data released for investigational maternal RSV vaccine; updates to Clozapine REMS; FDA panel votes on investigational CNS/leptomeningeal metastasis treatment.
USPSTF Recommends Against Postmenopausal Hormone Tx to Prevent Chronic Conditions
The recommendations were give a “D” grade indicating that there is moderate or high certainty that the harms associated with hormone therapy use in these settings outweigh any potential benefits.
Fezolinetant NDA Accepted for Vasomotor Symptoms Associated With Menopause
Fezolinetant is an investigational, nonhormonal selective neurokinin-3 receptor antagonist.
Hormone Therapy Not Tied to Breast Cancer Recurrence, Mortality
No increased risk seen for women using either vaginal estrogen therapy or menopausal hormone therapy after diagnosis
NAMS Updates Position Statement on Menopausal Hormone Therapy
Using best available evidence, treatment should be individualized to maximize benefits and minimize risks
Hormone Therapy-Related Hot Flashes Tied to Worse Breast Cancer Outcomes
Findings for chemotherapy-free patients with breast cancer
Odds of COVID-19 Mortality Lower for Women Receiving HRT
Receiving hormone replacement therapy within six months of recorded COVID-19 diagnosis linked to reduction in mortality
USPSTF Advises Against Hormone Therapy to Prevent Chronic Conditions
USPSTF recommends against hormone therapy for primary prevention of chronic conditions in postmenopausal persons
Suvorexant May Aid Insomnia Tied to Hot Flashes
Nighttime hot flashes, insomnia severity both down at four weeks versus placebo
